메뉴 건너뛰기




Volumn 12, Issue 1, 2014, Pages

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: Evaluation of biomarkers of immunologic and therapeutic response

Author keywords

HD IL 2; Melanoma; Radiotherapy; RCC

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; INTERLEUKIN 2; TUMOR MARKER;

EID: 84907780524     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0262-6     Document Type: Article
Times cited : (20)

References (53)
  • 1
    • 33751541698 scopus 로고    scopus 로고
    • The human T cell response to melanoma antigens
    • 17145305
    • Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol 2006, 92:187-224. 10.1016/S0065-2776(06)92005-7, 17145305.
    • (2006) Adv Immunol , vol.92 , pp. 187-224
    • Romero, P.1    Cerottini, J.C.2    Speiser, D.E.3
  • 2
    • 33750321707 scopus 로고    scopus 로고
    • Interferons, immunity and cancer immunoediting
    • 17063185
    • Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848. 10.1038/nri1961, 17063185.
    • (2006) Nat Rev Immunol , vol.6 , pp. 836-848
    • Dunn, G.P.1    Koebel, C.M.2    Schreiber, R.D.3
  • 4
    • 0036852241 scopus 로고    scopus 로고
    • Cancer immunoediting: from immunosurveillance to tumor escape
    • 12407406
    • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998. 10.1038/ni1102-991, 12407406.
    • (2002) Nat Immunol , vol.3 , pp. 991-998
    • Dunn, G.P.1    Bruce, A.T.2    Ikeda, H.3    Old, L.J.4    Schreiber, R.D.5
  • 5
    • 76749151403 scopus 로고    scopus 로고
    • Immune responses to malignancies
    • 20061007
    • Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010, 125:S272-S283. 10.1016/j.jaci.2009.09.045, 20061007.
    • (2010) J Allergy Clin Immunol , vol.125 , pp. S272-S283
    • Whiteside, T.L.1
  • 8
    • 84875039618 scopus 로고    scopus 로고
    • Combining radiotherapy and cancer immunotherapy: a paradigm shift
    • 23291374
    • Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013, 105:256-265. 10.1093/jnci/djs629, 23291374.
    • (2013) J Natl Cancer Inst , vol.105 , pp. 256-265
    • Formenti, S.C.1    Demaria, S.2
  • 9
    • 0033010852 scopus 로고    scopus 로고
    • Molecular mechanisms of ionizing radiation-induced apoptosis
    • 10361259
    • Watters D. Molecular mechanisms of ionizing radiation-induced apoptosis. Immunol Cell Biol 1999, 77:263-271. 10.1046/j.1440-1711.1999.00824.x, 10361259.
    • (1999) Immunol Cell Biol , vol.77 , pp. 263-271
    • Watters, D.1
  • 10
    • 0034920535 scopus 로고    scopus 로고
    • Dendritic cells resurrect antigens from dead cells
    • 11286729
    • Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001, 22:141-148. 10.1016/S1471-4906(01)01860-9, 11286729.
    • (2001) Trends Immunol , vol.22 , pp. 141-148
    • Larsson, M.1    Fonteneau, J.F.2    Bhardwaj, N.3
  • 12
    • 0027511929 scopus 로고
    • Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation
    • 8383862
    • Ishihara H, Tsuneoka K, Dimchev AB, Shikita M. Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 1993, 133:321-326. 10.2307/3578216, 8383862.
    • (1993) Radiat Res , vol.133 , pp. 321-326
    • Ishihara, H.1    Tsuneoka, K.2    Dimchev, A.B.3    Shikita, M.4
  • 13
    • 0024815235 scopus 로고
    • Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation
    • 2602359
    • Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A 1989, 86:10104-10107. 10.1073/pnas.86.24.10104, 2602359.
    • (1989) Proc Natl Acad Sci U S A , vol.86 , pp. 10104-10107
    • Hallahan, D.E.1    Spriggs, D.R.2    Beckett, M.A.3    Kufe, D.W.4    Weichselbaum, R.R.5
  • 14
    • 0035988623 scopus 로고    scopus 로고
    • Immune modulation by ionizing radiation and its implications for cancer immunotherapy
    • 12171547
    • Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002, 8:1765-1780. 10.2174/1381612023394089, 12171547.
    • (2002) Curr Pharm Des , vol.8 , pp. 1765-1780
    • Friedman, E.J.1
  • 15
    • 7444258053 scopus 로고    scopus 로고
    • Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
    • 15520206
    • Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994. 10.1158/0008-5472.CAN-04-1525, 15520206.
    • (2004) Cancer Res , vol.64 , pp. 7985-7994
    • Garnett, C.T.1    Palena, C.2    Chakraborty, M.3    Tsang, K.Y.4    Schlom, J.5    Hodge, J.W.6
  • 16
    • 0036494443 scopus 로고    scopus 로고
    • Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication
    • 11888921
    • Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002, 62:1462-1470. 11888921.
    • (2002) Cancer Res , vol.62 , pp. 1462-1470
    • Ganss, R.1    Ryschich, E.2    Klar, E.3    Arnold, B.4    Hammerling, G.J.5
  • 17
    • 0037111131 scopus 로고    scopus 로고
    • Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis
    • 12419448
    • Brooks PC, Roth JM, Lymberis SC, DeWyngaert K, Broek D, Formenti SC. Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis. Int J Radiat Oncol Biol Phys 2002, 54:1194-1201. 10.1016/S0360-3016(02)03748-3, 12419448.
    • (2002) Int J Radiat Oncol Biol Phys , vol.54 , pp. 1194-1201
    • Brooks, P.C.1    Roth, J.M.2    Lymberis, S.C.3    DeWyngaert, K.4    Broek, D.5    Formenti, S.C.6
  • 18
    • 0029803150 scopus 로고    scopus 로고
    • Cell adhesion molecules mediate radiationinduced leukocyte adhesion to the vascular endothelium
    • 8912850
    • Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiationinduced leukocyte adhesion to the vascular endothelium. Cancer Res 1996, 56:5150-5155. 8912850.
    • (1996) Cancer Res , vol.56 , pp. 5150-5155
    • Hallahan, D.1    Kuchibhotla, J.2    Wyble, C.3
  • 20
    • 25844459044 scopus 로고    scopus 로고
    • Combining radiotherapy and immunotherapy: a revived partnership
    • 16199306
    • Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005, 63:655-666. 10.1016/j.ijrobp.2005.06.032, 16199306.
    • (2005) Int J Radiat Oncol Biol Phys , vol.63 , pp. 655-666
    • Demaria, S.1    Bhardwaj, N.2    McBride, W.H.3    Formenti, S.C.4
  • 21
    • 36849031260 scopus 로고    scopus 로고
    • Sensors of ionizing radiation effects on the immunological microenvironment of cancer
    • 17852561
    • Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007, 83:819-825. 10.1080/09553000701481816, 17852561.
    • (2007) Int J Radiat Biol , vol.83 , pp. 819-825
    • Demaria, S.1    Formenti, S.C.2
  • 22
    • 0032471712 scopus 로고    scopus 로고
    • Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response
    • 9742914
    • Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998, 228:307-319. 10.1097/00000658-199809000-00004, 9742914.
    • (1998) Ann Surg , vol.228 , pp. 307-319
    • Rosenberg, S.A.1    Yang, J.C.2    White, D.E.3    Steinberg, S.M.4
  • 23
    • 0033847587 scopus 로고    scopus 로고
    • Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
    • 10685660
    • Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000, 6(Suppl 1):S55-S57. 10685660.
    • (2000) Cancer J Sci Am , vol.6 , pp. S55-S57
    • Fisher, R.I.1    Rosenberg, S.A.2    Fyfe, G.3
  • 24
    • 0033848628 scopus 로고    scopus 로고
    • High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update
    • 10685652
    • Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000, 6(Suppl 1):S11-S14. 10685652.
    • (2000) Cancer J Sci Am , vol.6 , pp. S11-S14
    • Atkins, M.B.1    Kunkel, L.2    Sznol, M.3    Rosenberg, S.A.4
  • 25
    • 36749041328 scopus 로고    scopus 로고
    • Interleukin 2: from immunostimulation to immunoregulation and back again
    • 18059313
    • Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 2007, 8:1142-1148. 10.1038/sj.embor.7401099, 18059313.
    • (2007) EMBO Rep , vol.8 , pp. 1142-1148
    • Bachmann, M.F.1    Oxenius, A.2
  • 27
  • 28
    • 41949097030 scopus 로고    scopus 로고
    • The biology of interleukin-2
    • 18062768
    • Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008, 26:453-479. 10.1146/annurev.immunol.26.021607.090357, 18062768.
    • (2008) Annu Rev Immunol , vol.26 , pp. 453-479
    • Malek, T.R.1
  • 30
    • 0030030641 scopus 로고    scopus 로고
    • Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
    • 8630945
    • Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996, 77:89-96. 10.1002/(SICI)1097-0142(19960101)77:1<89::AID-CNCR15>3.0.CO;2-4, 8630945.
    • (1996) Cancer , vol.77 , pp. 89-96
    • Legha, S.S.1    Gianan, M.A.2    Plager, C.3    Eton, O.E.4    Papadopoulous, N.E.5
  • 31
    • 0028929682 scopus 로고
    • Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
    • 7884429
    • Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696. 7884429.
    • (1995) J Clin Oncol , vol.13 , pp. 688-696
    • Fyfe, G.1    Fisher, R.I.2    Rosenberg, S.A.3    Sznol, M.4    Parkinson, D.R.5    Louie, A.C.6
  • 32
    • 0031812910 scopus 로고    scopus 로고
    • Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
    • 9708948
    • Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998, 83:797-805. 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M, 9708948.
    • (1998) Cancer , vol.83 , pp. 797-805
    • Kammula, U.S.1    White, D.E.2    Rosenberg, S.A.3
  • 33
    • 0034852781 scopus 로고    scopus 로고
    • Guidelines for the safe administration of high-dose interleukin-2
    • 11565830
    • Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001, 24:287-293. 10.1097/00002371-200107000-00004, 11565830.
    • (2001) J Immunother , vol.24 , pp. 287-293
    • Schwartzentruber, D.J.1
  • 34
    • 0023890374 scopus 로고
    • Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer
    • 3258545
    • Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988, 48:2561-2567. 3258545.
    • (1988) Cancer Res , vol.48 , pp. 2561-2567
    • Sondel, P.M.1    Kohler, P.C.2    Hank, J.A.3    Moore, K.H.4    Rosenthal, N.S.5    Sosman, J.A.6    Bechhofer, R.7    Storer, B.8
  • 36
    • 0026326748 scopus 로고
    • Continuous interleukin-2 and tumorinfiltrating lymphocytes as treatment of advanced melanoma. a national biotherapy study group trial
    • 2049729
    • Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Yannelli JR, Maleckar JR, Sferruzza A, Arnold J. Continuous interleukin-2 and tumorinfiltrating lymphocytes as treatment of advanced melanoma. a national biotherapy study group trial. Cancer 1991, 68:1-8. 10.1002/1097-0142(19910701)68:1<1::AID-CNCR2820680102>3.0.CO;2-K, 2049729.
    • (1991) Cancer , vol.68 , pp. 1-8
    • Dillman, R.O.1    Oldham, R.K.2    Barth, N.M.3    Cohen, R.J.4    Minor, D.R.5    Birch, R.6    Yannelli, J.R.7    Maleckar, J.R.8    Sferruzza, A.9    Arnold, J.10
  • 37
    • 3142688266 scopus 로고    scopus 로고
    • Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma
    • 15285881
    • Quan W, Brick W, Vinogradov M, Taylor WC, Khan N, Burgess R. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma. Cancer Biother Radiopharm 2004, 19:350-354. 10.1089/1084978041424972, 15285881.
    • (2004) Cancer Biother Radiopharm , vol.19 , pp. 350-354
    • Quan, W.1    Brick, W.2    Vinogradov, M.3    Taylor, W.C.4    Khan, N.5    Burgess, R.6
  • 38
    • 27444444916 scopus 로고    scopus 로고
    • Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells
    • 16224268
    • Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother 2005, 28:517-524. 10.1097/01.cji.0000177999.95831.7b, 16224268.
    • (2005) J Immunother , vol.28 , pp. 517-524
    • Hinrichs, C.S.1    Palmer, D.C.2    Rosenberg, S.A.3    Restifo, N.P.4
  • 39
    • 33644947935 scopus 로고    scopus 로고
    • Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    • 16425986
    • Hutson TE, Quinn DI. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?. Clin Genitourin Cancer 2005, 4:181-186. 10.3816/CGC.2005.n.030, 16425986.
    • (2005) Clin Genitourin Cancer , vol.4 , pp. 181-186
    • Hutson, T.E.1    Quinn, D.I.2
  • 40
    • 41849123889 scopus 로고    scopus 로고
    • Establishing the role of cytokine therapy in advanced renal cell carcinoma
    • 18279450
    • Gore ME, De Mulder P. Establishing the role of cytokine therapy in advanced renal cell carcinoma. BJU Int 2008, 101:1063-1070. 10.1111/j.1464-410X.2008.07435.x, 18279450.
    • (2008) BJU Int , vol.101 , pp. 1063-1070
    • Gore, M.E.1    De Mulder, P.2
  • 41
    • 33749443423 scopus 로고    scopus 로고
    • Interleukin-2 therapy of metastatic renal cell carcinoma-predictors of response
    • 17045087
    • McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma-predictors of response. Semin Oncol 2006, 33:583-587. 10.1053/j.seminoncol.2006.06.004, 17045087.
    • (2006) Semin Oncol , vol.33 , pp. 583-587
    • McDermott, D.F.1    Atkins, M.B.2
  • 42
    • 33846882806 scopus 로고    scopus 로고
    • Update on the application of interleukin-2 in the treatment of renal cell carcinoma
    • 17255299
    • McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 2007, 13:716s-720s. 10.1158/1078-0432.CCR-06-1872, 17255299.
    • (2007) Clin Cancer Res , vol.13 , pp. 716s-720s
    • McDermott, D.F.1
  • 43
    • 66849083515 scopus 로고    scopus 로고
    • Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy
    • 19364958
    • Kirkwood JM, Tarhini AA. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 2009, 27:2583-2585. 10.1200/JCO.2008.21.1540, 19364958.
    • (2009) J Clin Oncol , vol.27 , pp. 2583-2585
    • Kirkwood, J.M.1    Tarhini, A.A.2
  • 46
    • 84871773566 scopus 로고    scopus 로고
    • Novel agents in renal carcinoma: a reality check
    • 22754592
    • Najjar YG, Rini BI. Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol 2012, 4:183-194. 10.1177/1758834012443725, 22754592.
    • (2012) Ther Adv Med Oncol , vol.4 , pp. 183-194
    • Najjar, Y.G.1    Rini, B.I.2
  • 48
    • 65549167833 scopus 로고    scopus 로고
    • Targeting the mTOR signalling network for cancer therapy
    • 19332717
    • Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signalling network for cancer therapy. J Clin Oncol 2009, 27:2278-2287. 10.1200/JCO.2008.20.0766, 19332717.
    • (2009) J Clin Oncol , vol.27 , pp. 2278-2287
    • Meric-Bernstam, F.1    Gonzalez-Angulo, A.M.2
  • 50
    • 84877093633 scopus 로고    scopus 로고
    • Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control
    • 23444228
    • Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013, 19:2232-2239. 10.1158/1078-0432.CCR-12-3080, 23444228.
    • (2013) Clin Cancer Res , vol.19 , pp. 2232-2239
    • Robert, C.1    Schadendorf, D.2    Messina, M.3    Hodi, F.S.4    O'Day, S.5
  • 51
    • 84880278490 scopus 로고    scopus 로고
    • High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?
    • Amin A, White RL. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?. Oncology (Williston Park) 2013, 27:680-691.
    • (2013) Oncology (Williston Park) , vol.27 , pp. 680-691
    • Amin, A.1    White, R.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.